Human serum albumin is the most abundant protein in humanblood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. It is soluble and monomeric.
Albumin transports hormones, fatty acids, and other compounds, buffers pH, and maintains osmotic pressure, among other functions.
Albumin is synthesized in the liver as preproalbumin, which has an N-terminal peptide that is removed before the nascent protein is released from the rough endoplasmic reticulum. The product, proalbumin, is in turn cleaved in the Golgi vesicles to produce the secreted albumin.
The reference range for albumin concentrations in serum is approximately 35 - 50 g/L (3.5 - 5.0 g/dL). It has a serum half-life of approximately 20 days. It has a molecular mass of 67 kDa.
The gene for albumin is located on chromosome 4 and mutations in this gene can result in anomalous proteins. The human albumin gene is 16,961 nucleotides long from the putative 'cap' site to the first poly(A) addition site. It is split into 15 exons that are symmetrically placed within the 3 domains thought to have arisen by triplication of a single primordial domain.
Typically, this condition is a sign of severe or chronic dehydration. Chronic dehydration needs to be treated with zinc as well as with water. Zinc reduces cell swelling caused by decreased intake of water (hypotonicity) and also increases retention of salt. In the dehydrated state, the body has too high an osmolarity and, it appears, discards zinc to prevent this. Zinc also regulates transport of the cellular osmolyte taurine, and albumin is known to increase cellular taurine absorption. Zinc has been shown to increase retinol (vitamin A) production from beta-carotene, and in lab experiments retinol reduced human albumin production. It is possible that a retinol (vitamin A) deficiency alone could cause albumin levels to become raised. Patients recovering from chronic dehydration may develop dry eyes as the body uses up its vitamin A store. Retinol causes cells to swell with water (this is most likely one reason that too much vitamin A is toxic). Hyperalbuminemia is also associated with high protein diets.
Human albumin solution or HSA is available for medical use, usually at concentrations of 5-25%.
Human albumin is often used to replace lost fluid and help restore blood volume in trauma, burns and surgery patients. A Cochranesystematic review of 37 trials found no evidence that albumin, compared with cheaper alternatives such as saline, reduces the risk of dying.
Human serum albumin has been used as a component of a frailty index.
It has not been shown to give better results than other fluids when used simply to replace volume, but is frequently used in conditions where loss of albumin is a major problem, such as liver disease with ascites.
It has been known for a long time that human blood proteins like hemoglobin and serum albumin may undergo a slow non-enzymatic glycation, mainly by formation of a Schiff base between ε-amino groups of lysine (and sometimes arginine) residues and glucose molecules in blood (Maillard reaction). This reaction can be inhibited in the presence of antioxidant agents. Although this reaction may happen normally, elevated glycoalbumin is observed in diabetes mellitus.
Glycation has the potential to alter the biological structure and function of the serum albumin protein.
Moreover, the glycation can result in the formation of Advanced Glycosylation End-Products (AGE), which result in abnormal biological effects. Accumulation of AGEs leads to tissue damage via alteration of the structures and functions of tissue proteins, stimulation of cellular responses, through receptors specific for AGE-proteins, and generation of reactive oxygen intermediates. AGEs also react with DNA, thus causing mutations and DNA transposition. Thermal processing of proteins and carbohydrates brings major changes in allergenicity. AGEs are antigenic and represent many of the important neoantigens found in cooked or stored foods. They also interfere with the normal product of nitric oxide in cells.
Although there are several lysine and arginine residues in the serum albumin structure, very few of them can take part in the glycation reaction. It is not clear exactly why only these residues are glycated in serum albumin, but it is suggested that non-covalent binding of glucose to serum albumin prior to the covalent bond formation might be the reason.
Loss via kidneys
In the healthy kidney, albumin's size and negative electric charge exclude it from excretion in the glomerulus. This is not always the case, as in some diseases including diabetic nephropathy, a major complication of uncontrolled diabetes in which proteins can cross the glomerulus. The lost albumin can be detected by a simple urine test. Depending on the amount of albumin lost, a patient may have normal renal function, microalbuminuria, or albuminuria.
Amino acid sequence
The approximate sequence of human serum albumin is:
The italicized first 24 amino acids are signal and propeptide portions not observed in the transcribed, translated, and transported protein but present in the gene. There are 609 amino acids in this sequence with only 585 amino acids in the final product observed in the blood.
^Pasantes-Morales H, Wright CE, Gaull GE (December 1984). "Protective effect of taurine, zinc and tocopherol on retinol-induced damage in human lymphoblastoid cells". J. Nutr.114 (12): 2256–61. PMID6502269.
^Mutlu EA, Keshavarzian A, Mutlu GM (June 2006). "Hyperalbuminemia and elevated transaminases associated with high-protein diet". Scand. J. Gastroenterol.41 (6): 759–60. doi:10.1080/00365520500442625. PMID16716979.
^ abDay JF, Thorpe SR, Baynes JW (February 1979). "Nonenzymatically glucosylated albumin. In vitro preparation and isolation from normal human serum". J. Biol. Chem.254 (3): 595–7. PMID762083.
^ abcIberg N, Flückiger R (October 1986). "Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites". J. Biol. Chem.261 (29): 13542–5. PMID3759977.
^Jakus V, Hrnciarová M, Cársky J, Krahulec B, Rietbrock N (1999). "Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with antioxidant activity". Life Sci.65 (18–19): 1991–3. doi:10.1016/S0024-3205(99)00462-2. PMID10576452.
^Mohamadi-Nejad A, Moosavi-Movahedi AA, Hakimelahi GH, Sheibani N (September 2002). "Thermodynamic analysis of human serum albumin interactions with glucose: insights into the diabetic range of glucose concentration". Int. J. Biochem. Cell Biol.34 (9): 1115–24. doi:10.1016/S1357-2725(02)00031-6. PMID12009306.
^Shaklai N, Garlick RL, Bunn HF (March 1984). "Nonenzymatic glycosylation of human serum albumin alters its conformation and function". J. Biol. Chem.259 (6): 3812–7. PMID6706980.
^Mendez DL, Jensen RA, McElroy LA, Pena JM, Esquerra RM (December 2005). "The effect of non-enzymatic glycation on the unfolding of human serum albumin". Arch. Biochem. Biophys.444 (2): 92–9. doi:10.1016/j.abb.2005.10.019. PMID16309624.
^Mohamadi-Nejada A, Moosavi-Movahedi AA,Safariana S, Naderi-Maneshc MH, Ranjbarc B, Farzamid B, Mostafavie H, Larijanif MB, Hakimelahi GH, A (July 2002). "The thermal analysis of nonezymatic glycosylation of human serum albumin: differential scanning calorimetry and circular dichroism studies". Thermochimica Acta389 (1–2): 141–151. doi:10.1016/S0040-6031(02)00006-0.
^Kańska U, Boratyński J (2002). "Thermal glycation of proteins by D-glucose and D-fructose". Arch. Immunol. Ther. Exp. (Warsz.)50 (1): 61–6. PMID11916310.
^Rojas A, Romay S, González D, Herrera B, Delgado R, Otero K (February 2000). "Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products". Circ. Res.86 (3): E50–4. PMID10679490.
^Garlick RL, Mazer JS (May 1983). "The principal site of nonenzymatic glycosylation of human serum albumin in vivo". J. Biol. Chem.258 (10): 6142–6. PMID6853480.
^Marashi SA, Safarian S, Moosavi-Movahedi AA (2005). "Why major nonenzymatic glycation sites of human serum albumin are preferred to other residues?". Med. Hypotheses64 (4): 881. doi:10.1016/j.mehy.2004.11.007. PMID15694713.
Komatsu T, Nakagawa A, Curry S, et al. (2009). "The role of an amino acid triad at the entrance of the heme pocket in human serum albumin for O(2) and CO binding to iron protoporphyrin IX". Org. Biomol. Chem.7 (18): 3836–41. doi:10.1039/b909794e. PMID19707690.
Silva AM, Hider RC (2009). "Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation". Biochim. Biophys. Acta1794 (10): 1449–58. doi:10.1016/j.bbapap.2009.06.003. PMID19505594.
Otosu T, Nishimoto E, Yamashita S (2010). "Multiple conformational state of human serum albumin around single tryptophan residue at various pH revealed by time-resolved fluorescence spectroscopy". J. Biochem.147 (2): 191–200. doi:10.1093/jb/mvp175. PMID19884191.
Juárez J, Lápez SG, Cambán A, et al. (2009). "Influence of electrostatic interactions on the fibrillation process of human serum albumin". J Phys Chem B113 (30): 10521–9. doi:10.1021/jp902224d. PMID19572666.
Fu BL, Guo ZJ, Tian JW, et al. (2009). "[Advanced glycation end products induce expression of PAI-1 in cultured human proximal tubular epithelial cells through NADPH oxidase dependent pathway]". Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi25 (8): 674–7. PMID19664386.
Curry S (2002). "Beyond expansion: structural studies on the transport roles of human serum albumin". Vox Sang. 83 Suppl 1: 315–9. PMID12617161.
Guo S, Shi X, Yang F, et al. (2009). "Structural basis of transport of lysophospholipids by human serum albumin". Biochem. J.423 (1): 23–30. doi:10.1042/BJ20090913. PMID19601929.
de Jong PE, Gansevoort RT (2009). "Focus on microalbuminuria to improve cardiac and renal protection". Nephron Clin Pract111 (3): c204–10; discussion c211. doi:10.1159/000201568. PMID19212124.
Page TA, Kraut ND, Page PM, et al. (2009). "Dynamics of loop 1 of domain I in human serum albumin when dissolved in ionic liquids". J Phys Chem B113 (38): 12825–30. doi:10.1021/jp904475v. PMID19711930.
Cui FL, Yan YH, Zhang QZ, et al. (2010). "A study on the interaction between 5-Methyluridine and human serum albumin using fluorescence quenching method and molecular modeling". J Mol Model16 (2): 255–62. doi:10.1007/s00894-009-0548-4. PMID19588173.
Caridi G, Dagnino M, Simundic AM, et al. (2010). "Albumin Benkovac (c.1175 A > G; p.Glu392Gly): a novel genetic variant of human serum albumin". Transl Res155 (3): 118–9. doi:10.1016/j.trsl.2009.10.001. PMID20171595.
Deeb O, Rosales-Hernández MC, Gámez-Castro C, et al. (2010). "Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand-protein interactions". Biopolymers93 (2): 161–70. doi:10.1002/bip.21314. PMID19785033.
Karahan SC, Koramaz I, Altun G, et al. (2010). "Ischemia-modified albumin reduction after coronary bypass surgery is associated with the cardioprotective efficacy of cold-blood cardioplegia enriched with N-acetylcysteine: a preliminary study". Eur Surg Res44 (1): 30–6. doi:10.1159/000262324. PMID19955769.
Jin C, Lu L, Zhang RY, et al. (2009). "Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus". Clin. Chim. Acta408 (1–2): 45–9. doi:10.1016/j.cca.2009.07.003. PMID19615354.